ESMO 2023 | MARIPOSA-2: amivantamab + chemo (± lazertinib) vs chemo in EGFR-mutated NSCLC post-osimertinib

Antonio Passaro, MD, PhD, European Institute of Oncology, Milan, Italy, discusses the Phase III MARIPOSA-2 (NCT04988295) trial, exploring the effectiveness of amivantamab (ami) in combination with carboplatin-pemetrexed (chemo) with or without lazertinib (laz) in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who had experienced disease progression on osimertinib. The trial demonstrated significant improvements in progression-free survival (PFS), objective response rate (ORR), and intracranial PFS for both ami-chemo and ami-laz-chemo compared to chemo alone. The interim overall-survival (OS) data showed promising trends. Hematologic, EGFR, and MET-related adverse events were observed in the ami-containing arms, with lower hematologic toxicity in the ami-chemo arm. Longer-term follow-up is needed to assess the impact of regimen modifications on safety and efficacy. These findings suggest that ami-chemo and ami-laz-chemo could become a new standard of care for EGFR-mutated advanced NSCLC patients who progressed on osimertinib. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.